Department of Medicine, Hematology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Cells. 2020 Sep 29;9(10):2199. doi: 10.3390/cells9102199.
The concentration of circulating hematopoietic stem and progenitor cells has not been studied longitudinally. Here, we report that the proportions of Lin-CD34+38- hematopoietic multipotent cells (HMCs) and of Lin-CD34+CD38+ hematopoietic progenitors cells (HPCs) are highly variable between individuals but stable over long periods of time, in both healthy individuals and sickle cell disease (SCD) patients. This suggests that these proportions are regulated by genetic polymorphisms or by epigenetic mechanisms. We also report that in SCD patients treated with hydroxyurea, the proportions of circulating HMCs and HPCs show a strong positive and negative correlation with fetal hemoglobin (HbF) levels, respectively. Titration of 65 cytokines revealed that the plasma concentration of chemokines CCL2, CCL11, CCL17, CCL24, CCL27, and PDGF-BB were highly correlated with the proportion of HMCs and HPCs and that a subset of these cytokines were also correlated with HbF levels. A linear model based on four of these chemokines could explain 80% of the variability in the proportion of circulating HMCs between individuals. The proportion of circulating HMCs and HPCs and the concentration of these chemokines might therefore become useful biomarkers for HbF response to HU in SCD patients. Such markers might become increasingly clinically relevant, as alternative treatment modalities for SCD are becoming available.
循环造血干/祖细胞的浓度尚未进行纵向研究。在这里,我们报告称,Lin-CD34+38-造血多能细胞(HMC)和 Lin-CD34+CD38+造血祖细胞(HPC)的比例在个体之间差异很大,但在健康个体和镰状细胞病(SCD)患者中,这些比例在很长一段时间内都保持稳定。这表明这些比例受到遗传多态性或表观遗传机制的调节。我们还报告称,在接受羟基脲治疗的 SCD 患者中,循环 HMC 和 HPC 的比例与胎儿血红蛋白(HbF)水平呈强正相关和负相关。对 65 种细胞因子的滴定表明,趋化因子 CCL2、CCL11、CCL17、CCL24、CCL27 和 PDGF-BB 的血浆浓度与 HMC 和 HPC 的比例高度相关,其中一部分细胞因子也与 HbF 水平相关。基于这四种趋化因子的线性模型可以解释个体之间循环 HMC 比例变化的 80%。因此,循环 HMC 和 HPC 的比例以及这些趋化因子的浓度可能成为 SCD 患者对 HU 反应的 HbF 的有用生物标志物。随着 SCD 的替代治疗方法的出现,这些标志物可能会变得越来越具有临床意义。